19日の米株式市場で米バイオテクノロジー企業ノババックスの株価が急伸した。米規制当局が同社の新型コロナウイルスワクチンを完全に承認したことで、承認遅延や有効性を疑問視するケネディ厚生長官の発言により高まっていた市場の不安が和らいだ。

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

The U.S. Food and Drug Administration approved Novavax's Covid-19 vaccine with age restrictions after a six-week delay.

Coinbase Global (COIN) will begin trading on the S&P 500 (^GSPC) effective today, replacing Discover Financial Services (DFS) ...